Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.
Xueliang GaoYubao WangCaroline Fidalgo RibeiroCherubin ManokaranHyeyoun ChangThanh VonSilvia RodriguesOnur CizmeciogluShidong JiaManav KorpalJoshua M KornZhigang WangFabienne SchmitLan JiangRaymond PagliariniYi YangIsha SethiSabina SignorettiGuo-Cheng YuanMassimo LodaJean J ZhaoThomas M RobertsPublished in: Molecular cancer research : MCR (2022)
This work establishes p110β as a promising target for preventing the progression of primary PTEN-deficient prostate tumors to CRPC, and for treating established CRPC in combination with RAC/PAK1 or tankyrase inhibitors.